RESEARCH OVERVIEW
Lishui Central Hospital has consistently adhered to the development strategy of ‘revitalizing the hospital through science and education, and strengthening it with talent.’ The hospital has established an integrated development model that combines education, scientific research, and talent cultivation, actively advancing the construction of a research-oriented institution and promoting its high-quality development.
The hospital has established a national post-doctoral research workstation and a provincial academician workstation. It also hosts three major platforms: a provincial key laboratory, a provincial engineering research center, and a provincial international scientific and technological cooperation base. In 2024, it was designated as one of the first batch of research-oriented hospital cultivation units in Zhejiang Province, and remains the only institution in the city to receive this recognition.
The hospital encompasses 2 national key clinical specialties under construction, 4 provincial key clinical specialties under construction, 2 provincially supported key disciplines, 4 key disciplines jointly developed by the province and the city, 6 provincial regional disease centers, 3 key disciplines of Wenzhou Medical University, 2 key discipline groups of Wenzhou Medical University, 5 Lishui medical peak disciplines, 5 municipal key clinical specialties under construction, and 16 Lishui key disciplines.
Since obtaining national certification for drug clinical trials in 2017, the hospital has consistently taken a leading role in the development of regional clinical trials through its strong research capabilities and standardized management practices. The clinical trial center is authorized for 22 pharmaceutical specialties and 22 medical device specialties, with more than 60 registered Principal Investigators (PIs). Its research covers advanced fields such as cardiovascular medicine, oncology, critical care medicine, and Phase I clinical trial laboratories. The hospital remains the only institution in Lishui qualified to conduct comprehensive drug clinical trials, with over 100 active projects annually. To date, it has undertaken more than 300 clinical trials of new drugs (Phases I–IV) and medical devices from both domestic and international sources. The volume and quality of its projects consistently rank among the top municipal hospitals in Zhejiang Province. The institution’s efficient, standardized processes have earned high recognition from sponsors, contract research organizations (CROs), and clinical research coordinators (CRCs).
In 2024, the hospital made remarkable progress in securing national-level research projects, obtaining a total of 6 national projects, 6 ministerial-level projects, and 126 municipal-level projects. For the first time, the hospital was approved for key special projects under the ‘14th Five-Year Plan’ and regional joint key projects of the National Natural Science Foundation of China—both representing historic firsts for Lishui . Additionally, the hospital received approval for 3 national-level projects, including the Young Scholar Training Program under the National Key Research and Development Program and the General Program of the National Natural Science Foundation of China. It also participated as the task-leading unit in 1 National Key Research and Development Program project. Throughout the year, the hospital published more than 300 scientific papers, including over 120 indexed in the Science Citation Index (SCI), and was granted 37 authorized patents. Notably, one of the hospital’s nationally recognized leading talents was named among the world’s top 2% of scientists for the third consecutive year and was listed among the top 1% of highly cited scholars in the 2024 China Knowledge Network ranking.
浙公网安备 33110202000177号